{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(8)"],"submitter":["Chiang CH"],"pubmed_abstract":["<h4>Background</h4>Certain angiotensin receptor blockers (ARBs) have peroxisome proliferator-activated receptor-γ (PPAR-γ) activation property, which has been associated with improved programmed cell death ligand 1 blockade and cytotoxic T lymphocyte-mediated antitumor activity.<h4>Methods</h4>We conducted a retrospective cohort study to investigate the impact of PPAR-γ-activating ARBs on patient survival in patients treated with immune checkpoint inhibitors (ICIs) across all types of cancers.<h4>Results</h4>A total of 167 patients receiving both angiotensin receptor blockers (ARBs) and immune checkpoint inhibitors (ICIs) were included. Compared with non-PPAR-γ-ARB users (n = 102), PPAR-γ-ARB users (n = 65) had a longer median overall survival (not reached [IQR, 16.0-not reached] vs. 18.6 "],"journal":["Cancer medicine"],"pagination":["9583-9588"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10166924"],"repository":["biostudies-literature"],"pubmed_title":["The impact of peroxisome proliferator-activated receptor-γ activating angiotensin receptor blocker on outcomes of patients receiving immunotherapy."],"pmcid":["PMC10166924"],"pubmed_authors":["See XY","Peng CY","Peng CM","Hsia YP","Chen YJ","Chiang CH","Wang SS","Chang YC"],"additional_accession":[]},"is_claimable":false,"name":"The impact of peroxisome proliferator-activated receptor-γ activating angiotensin receptor blocker on outcomes of patients receiving immunotherapy.","description":"<h4>Background</h4>Certain angiotensin receptor blockers (ARBs) have peroxisome proliferator-activated receptor-γ (PPAR-γ) activation property, which has been associated with improved programmed cell death ligand 1 blockade and cytotoxic T lymphocyte-mediated antitumor activity.<h4>Methods</h4>We conducted a retrospective cohort study to investigate the impact of PPAR-γ-activating ARBs on patient survival in patients treated with immune checkpoint inhibitors (ICIs) across all types of cancers.<h4>Results</h4>A total of 167 patients receiving both angiotensin receptor blockers (ARBs) and immune checkpoint inhibitors (ICIs) were included. Compared with non-PPAR-γ-ARB users (n = 102), PPAR-γ-ARB users (n = 65) had a longer median overall survival (not reached [IQR, 16.0-not reached] vs. 18.6 ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2025-04-22T00:34:22.446Z","creation":"2025-04-05T19:35:45.637Z"},"accession":"S-EPMC10166924","cross_references":{"pubmed":["36825549"],"doi":["10.1002/cam4.5734"]}}